MedTrace Logo

Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

NCT03300401 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2019-05-16

No results posted yet for this study

Summary

This pilot clinical trial studies how well contrast-enhanced ultrasound in diagnosing patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced ultrasound may provide detailed imaging of the tumor arteries after the injection of a contrast-agent consisting of microbubbles, and may predict how much Yttrium-90 will deposit in the tumor.

Conditions

Interventions

DRUG

Perflutren Lipid Microspheres

Receive intravenous injection just prior to ultrasound

DRUG

Sulfur Hexafluoride Lipid Microspheres

Receive intravenous injection just prior to ultrasound

DEVICE

Dynamic Contrast-Enhanced Ultrasound Imaging

Undergo Contrast-Enhanced Ultrasound Imaging

DEVICE

Positron Emission Tomography

Undergo PET/CT

DEVICE

Computed Tomography

Undergo CT scan

BIOLOGICAL

Yttrium-90 (90Y)

Given IV

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Southern California

    lead OTHER

Principal Investigators

  • Harshawn Malhi, MD · University of Southern California

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-07
Primary Completion
2019-11-07
Completion
2020-11-07
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03300401 on ClinicalTrials.gov